Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

Documenti analoghi

• Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
  di: Finn, Richard S., et al.
  Pubblicazione: (2009)
• An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
  di: Esteva, Francisco J., et al.
  Pubblicazione: (2013)
• Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
  di: Kim, Sung-Bae, et al.
  Pubblicazione: (2017)
• Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies
  di: Tan, A R, et al.
  Pubblicazione: (2014)
• Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma(†)
  di: Al-Batran, S.-E., et al.
  Pubblicazione: (2016)